Please login to the form below

Not currently logged in
Email:
Password:

Israel finds a ‘probable link’ between Pfizer vaccine and myocarditis cases

Reported cases increased following the second dose of the mRNA-based COVID-19 vaccine

A small number of cases of myocarditis – a type of heart inflammation – may be linked to the second dose of Pfizer’s BioNTech-partnered COVID-19 vaccine, Israel’s Health Ministry announced this week.

The cases, observed mostly in young men who had received the Pfizer/BioNTech jab, have a ‘probable link’ to the second dose of the vaccine, according to Israel.

Israel’s Health Ministry reported that it was aware of 275 cases of myocarditis occurring between December 2020 to May 2021, with 148 of these cases happening within a short time frame after receiving the Pfizer/BioNTech vaccine.

The ministry added that the majority were seen among men under the age of 30 years and particularly in those aged between 16 and 19 years old.

Of the 5,401,150 who had been given the vaccine within this time period, 27 myocarditis cases were reported, including in 11 people with pre-existing conditions, shortly after their first Pfizer/BioNTech vaccine dose.

This increased after the second dose, however, with 121 cases, including 60 people with pre-existing conditions, developing myocarditis within 30 days out of a total 5,049,424 fully vaccinated individuals in Israel.

The ministry added that most of the cases were mild, with one death linked to myocarditis but not conclusively proven.

Pfizer said that it is ‘aware’ of the reports and findings in Israel of myocarditis in vaccinated people, although it added that no causal link has yet been established.

Last month, a US Centers for Disease Control and Prevention (CDC) advisory group said that further study of myocarditis in young adults who have received mRNA-based COVID-19 vaccines. Pfizer/BioNTech and Moderna’s are the only two mRNA-based vaccines approved for use in the US.

In a statement, the CDC’s Advisory Committee on Immunization Practices said that it had evaluated cases among a very small number of adolescents and young adults who developed myocarditis following COVID-19 vaccination.

The CDC added that it had not seen more cases than would typically be expected in the population, although advisory committee members said that healthcare providers should be wary of the reports of the “potential adverse event”.

Article by
Lucy Parsons

2nd June 2021

From: Research

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 950 experts delivering world-class...

Latest intelligence

World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...
Pharmaceutical Marketing Strategies For The Digital Age
In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...